Mr. Shaun Flanagan:

Thank you. The other thing that has changed over the period of the introduction of the MCAP is that for one of the areas in particular, the epilepsy area, at the time that the MCAP was proposed, there was no medicine approved or authorised in the market. As Dr. Nolan said, there is now a medicine that is market authorised. The HSE obviously has a process around new medicines and how those are assessed, and that process is ongoing.

We are now at the stage when the health assessment is completed. Commercial negotiations are ongoing with the company. That is not part of the medical cannabis access programme, MCAP, as it is a licensed medicine. It is a separate medicine but some of the patients will in due course be covered, assuming it might be reimbursed. I am not sure if that answers the Deputy's question.